CepTor's Abstract on Myodur (C-101) Accepted for Platform Presentation at the American Academy of Neurology (AAN) Meeting.HUNT VALLEY, Md. -- CepTor Corporation (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:CEPO), a development-stage biopharmaceutical company focusing on cell-targeted therapeutic products for neuromuscular and neurodegenerative diseases, announced that its abstract: Biological Effects of a Potent, Muscle-Targeted, Orally Bioavailable Calpain cal·pain n. A proteolytic enzyme that is regulated by the concentration of calcium ions. [Probably cal(cium) + p(rote)a(se) + -in.] Inhibitor (C101) for Duchenne Muscular Dystrophy Duchenne muscular dystrophy (DMD) The most severe form of muscular dystrophy, DMD usually affects young boys and causes progressive muscle weakness, usually beginning in the legs. (DMD (1) (Digital Micromirror Device) See DLP. (2) (Digital Multi-layer Disk) See high-def DVD formats. ) has been accepted for a platform presentation at the 58th American Academy of Neurology The American Academy of Neurology (AAN) is a professional society for neurologists and neuroscientists. As a medical specialty society it was established in 1949 by A.B. Baker of the University of Minnesota to advance the art and science of neurology, and thereby promote the best Annual Meeting, April 1-8, 2006 at the San Diego Convention Center The San Diego Convention Center is the main convention center for the city of San Diego, California. It is located in the Marina district of downtown San Diego near the Gaslamp Quarter, at 111 West Harbor Drive. in San Diego, CA. Specifically, CepTor will present at Session S46: Muscle Diseases: Genetic and Inflammatory Muscle Diseases on Thursday, April 6, 2006 at 1:45 p.m. CepTor recently submitted an Investigational New Drug application (IND) for Myodur to initiate a phase 1-2 clinical trial in Duchenne boys. Norman Barton, M.D., PhD, CepTor's Executive Vice President and Chief Medical Officer, stated, "This presents an exciting opportunity to discuss important preclinical data on Myodur with the neurological community." William Pursley, CepTor Chairman and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , added, "For the first time, we finally get to share our data with the world at this most appropriate venue, while protecting our publication plans." About CepTor CepTor Corporation is a development-stage biopharmaceutical company engaged in the discovery, development, and commercialization of proprietary, cell-targeted therapeutic products for the treatment of neuromuscular and neurodegenerative diseases with a focus on orphan diseases. The Company's mission is to increase the quality and quantity of life of people suffering with these diseases. An orphan disease is defined in the United States as a serious or life-threatening disease that affects less than 200,000 people and for which no definitive therapy currently exists. CepTor Corporation seeks to create an efficient orphan drug platform by taking advantage of the legislative, regulatory and commercial opportunities common to these rare diseases. CepTor's primary efforts are currently being focused on moving its lead product, Myodur, into phase I/II clinical trials for Duchenne muscular dystrophy. The Company's broad platform technology also includes the development of products for multiple sclerosis and chronic inflammatory demyelinating polyneuropathy Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated inflammatory disorder of the peripheral nervous system but often can have central nervous system involvement. The disorder is sometimes called chronic relapsing polyneuropathy. (CIDP). This news release contains forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. review process and other government regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion